Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group.

Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23.

PMID:
28237263
2.

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group.

N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.

3.

Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.

Abraham WT, Decaux G, Josiassen RC, Yagil Y, Kopyt N, Thacker HP, Mannelli M, Bichet DG, Orlandi C; HARMONY Study Group.

Kidney Int. 2012 Dec;82(11):1215-22. doi: 10.1038/ki.2012.274. Epub 2012 Aug 29.

4.

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators.

Lancet Neurol. 2012 Mar;11(3):225-31. doi: 10.1016/S1474-4422(12)70017-0. Epub 2012 Feb 1.

PMID:
22305462
5.

Left pulmonary artery hypoplasia presenting with unilateral hyperluscent lung.

Sunavala AJ, Thacker HP, Khann JN.

J Assoc Physicians India. 2011 Mar;59:179-81.

PMID:
21751632
6.

Apixaban in patients with atrial fibrillation.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators.

N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.

7.
8.

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Indian Polycap Study (TIPS), Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N.

Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.

PMID:
19339045
9.

Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).

Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, Guindy R, Chopra P, Moller RA, Schou IM; Gemini-AALA Investigators.

J Hum Hypertens. 2009 Mar;23(3):196-210. doi: 10.1038/jhh.2008.114. Epub 2008 Sep 18.

PMID:
18800143
10.

S-amlodipine--the 2007 clinical review.

Thacker HP.

J Indian Med Assoc. 2007 Apr;105(4):180-2, 184, 186 passim.

PMID:
17822186
11.

Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.

Pai VG, Pai NV, Thacker HP, Shinde JK, Mandora VP, Erram SS.

World J Gastroenterol. 2006 Oct 7;12(37):6017-20.

Supplemental Content

Loading ...
Support Center